Nordanalyt Laboratories
The slowest and most precise contributor. The only lab here offering ion-pair, SEC and ICP-MS as routine. 511 reports in the index — 7.6 % of the total.
Identification and method basis
- Laboratory
- Nordanalyt Laboratories
- Short code in this index
- Nordanalyt
- Location
- Uppsala, Sweden
- Founded
- 2016
- Reports contributed
- 511
- Share of index
- 7.6%
- Purity gradient
- 35min
- Mass resolution
- High resolution (ESI-TOF / QTOF)
- Stated turnaround
- 10–18 business days
- Measured offset vs reference
- -0.005 pp
- Within-lab repeatability
- 0.16pp
Nordanalyt is a contract analytical laboratory that took index submissions from 2024-Q3 onward. It is the most capable contributor in the index on methods and the least convenient on turnaround, and its record set is correspondingly small and unusually rich.
Three capabilities exist nowhere else in the index. Ion-pair chromatography makes the short bioregulator class — carnosine, vilon, pinealon, epitalon — genuinely assayable rather than nominally assayable, and Nordanalyt is the source of every report in that class that the index does not mark method-inappropriate. Size-exclusion chromatography allows the recombinant and conjugated compounds (IGF-1 LR3, IGF-1 DES, PEG-MGF, follistatin-344) to be characterised for aggregate content, which reverse-phase chromatography cannot do. And ICP-MS gives a copper number for GHK-Cu and a zinc number for thymulin, which is the difference between a complete and an incomplete report on those two compounds.
Repeatability is the best in the index at 0.16 pp, helped by duplicate injection as standard. Measured bias is +0.02 pp on 74 paired comparisons — indistinguishable from the reference despite the 35-minute gradient, which is mildly surprising and is discussed on the inter-lab page.
The constraint is throughput. Nordanalyt's median turnaround in the index is 14 days and its cost per full panel is several times that of the faster laboratories, so it is used for difficult compounds and disputed results rather than routine screening.
Methods offered
What a laboratory can measure decides what a record can establish. A submission that orders only purity produces a record that names nothing.
- RP-HPLC purity (%area, 214 nm), duplicate injection
- LC-MS/MS identity and sequence confirmation
- ion-pair chromatography for short and charged peptides
- size-exclusion chromatography for aggregates and conjugates
- Karl Fischer water
- counter-ion by ion chromatography
- residual solvents by GC headspace, ICH Q3C(R8)
- ICP-MS for metal-complexed peptides
What this laboratory has measured
| Compound class | Reports | Median purity | Method suitability |
|---|---|---|---|
| Incretin analogues and co-agonists | 183 | 98.68 | ADEQUATE |
| Growth-hormone axis peptides | 92 | 99.04 | ADEQUATE |
| Tissue-repair and immunomodulatory peptides | 87 | 99.43 | ADEQUATE |
| Melanocortin-receptor peptides | 40 | 99.34 | ADEQUATE |
| Non-peptide adjuncts | 33 | 99.40 | ADEQUATE |
| Neuroactive and cognitive peptides | 32 | 99.34 | ADEQUATE |
| Short bioregulator peptides | 17 | 99.09 | ADEQUATE |
| Metabolic and mitochondrial peptides | 16 | 99.38 | ADEQUATE |
| Hypothalamic and posterior-pituitary hormones | 11 | 99.22 | ADEQUATE |
| Most-tested compounds here | Reports | Median purity |
|---|---|---|
| Semaglutide | 73 | 98.96 |
| Tirzepatide | 46 | 98.52 |
| Retatrutide | 38 | 98.34 |
| BPC-157 | 33 | 99.36 |
| TB-500 | 28 | 99.69 |
| Ipamorelin | 18 | 99.41 |
| PT-141 (Bremelanotide) | 18 | 99.31 |
| Semax | 15 | 99.17 |
| GHRP-2 | 14 | 99.21 |
| GHRP-6 | 14 | 99.55 |
| CJC-1295 with DAC | 13 | 98.61 |
| MK-677 (Ibutamoren mesylate) | 12 | 99.76 |
| CJC-1295 (no DAC) | 10 | 98.04 |
| Liraglutide | 9 | 99.23 |
| Sermorelin | 9 | 98.71 |
| NAD+ | 9 | 98.84 |
Agreement with the other laboratories
Each row is a paired analysis: batches where this laboratory and another one both assayed the same physical lot. A difference on a matched pair is bias plus noise, and it is the only clean way to compare laboratories.
| Against | Paired lots | Mean difference (pp) | 95 % limits of agreement | Within 0.5 pp |
|---|---|---|---|---|
| Janoshik | 357 | -0.005 | -0.72 to 0.71 | 84% |
| PeptideMeter | 244 | +0.020 | -0.78 to 0.82 | 77% |
| Medutest | 224 | -0.110 | -0.94 to 0.72 | 75% |
| VendorInvestigate | 174 | +0.498 | -0.27 to 1.26 | 51% |
| Kestrel | 138 | -0.328 | -1.30 to 0.65 | 65% |
Positive means Nordanalyt read higher. The full paired analysis, with its assumptions →
Provenance of what this laboratory receives
A laboratory that mostly receives supplier-supplied samples produces a record set with a known upward pressure on it, however good its analysis is. This is a property of the submission channel and not of the laboratory.
| Provenance | Reports | Share | Evidentiary weight | |
|---|---|---|---|---|
| Buyer-sourced | 41 | 8.0% | Strongest available evidence in this index. | |
| Supplier-supplied | 441 | 86.3% | Weaker evidence. Read with the caveat below. | |
| Laboratory-retained | 29 | 5.7% | Provenance documented, selection uncontrolled. |
Recent records from this laboratory
| Report | Compound | Supplier | Lot | Quarter | Purity % | Water % | Recovery % | Provenance | Flags | Result |
|---|---|---|---|---|---|---|---|---|---|---|
| AX-2026-041847 | TB-500 | JEEP | JEEP-2602-V3434 | 2026-Q3 | 99.72 | 3.85 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041275 | Liraglutide | WWB | WWB-2607-X2189 | 2026-Q3 | 99.61 | 5.03 | 97.3 | Supplier-supplied | 0 | PASS |
| AX-2026-042368 | Semax | HJ | HJ-2603-V4363 | 2026-Q3 | 99.17 | 7.26 | 106.3 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041886 | Semaglutide | JEEP | JEEP-2607-X3911 | 2026-Q3 | 99.19 | 4.03 | 96.4 | Supplier-supplied | 2 | MARGINAL |
| AX-2026-041337 | Semaglutide | WWB | WWB-2606-N3192 | 2026-Q3 | 98.96 | 4.81 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041452 | Retatrutide | QYB | QYB-2604-B5660 | 2026-Q3 | 98.50 | 3.36 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041882 | Semaglutide | JEEP | JEEP-2607-X3911 | 2026-Q3 | 99.17 | 4.52 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042398 | Semaglutide | SWB | SWB-2602-X5278 | 2026-Q3 | 99.08 | 4.48 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043367 | N-Acetyl Semax Amide | CPC | CPC-2602-D2941 | 2026-Q3 | 99.39 | 6.16 | 92.4 | Supplier-supplied | 0 | PASS |
| AX-2026-042388 | Semaglutide | SWB | SWB-2602-X5278 | 2026-Q3 | 98.09 | 3.90 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041652 | Liraglutide | QSC | QSC-2605-W8602 | 2026-Q3 | 99.33 | 6.55 | — | Supplier-supplied | 0 | PASS |
| AX-2026-042463 | Kisspeptin-10 | SWB | SWB-2603-D6238 | 2026-Q3 | 98.35 | 4.93 | 98.6 | Supplier-supplied | 3 | FAIL |
| AX-2026-042185 | Ipamorelin | Homopeptide | HOMO-2608-A9045 | 2026-Q3 | 99.26 | 4.63 | 95.0 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042799 | Selank | GGPeps | GGPE-2602-G2056 | 2026-Q3 | 98.77 | 8.33 | — | Supplier-supplied | 0 | FAIL |
| AX-2026-042348 | Semaglutide | HJ | HJ-2608-C3931 | 2026-Q3 | 99.52 | 4.19 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041979 | Humanin (HNG) | TFC | TFC-2605-U5564 | 2026-Q3 | 99.73 | 6.64 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-042058 | Sermorelin | TFC | TFC-2605-Y6440 | 2026-Q3 | 98.71 | 3.69 | 107.1 | Supplier-supplied | 0 | PASS |
| AX-2026-043400 | Semaglutide | WXT | WXT-2604-C4728 | 2026-Q3 | 96.86 | 4.11 | 106.4 | Laboratory-retained | 1 | FAIL |
| AX-2026-041975 | Humanin (HNG) | TFC | TFC-2605-U5564 | 2026-Q3 | 99.93 | 6.86 | 91.5 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043317 | Tirzepatide | CPC | CPC-2607-L2552 | 2026-Q3 | 96.43 | 5.42 | 106.4 | Supplier-supplied | 2 | FAIL |
| AX-2026-043032 | Retatrutide | KP | KP-2607-H5219 | 2026-Q3 | 96.69 | 5.87 | — | Supplier-supplied | 2 | MARGINAL |
| AX-2026-042668 | CJC-1295 (no DAC) | GGPeps | GGPE-2606-E8495 | 2026-Q3 | 98.02 | 4.53 | 103.9 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041774 | Semaglutide | FGP | FGP-2602-M1508 | 2026-Q3 | 99.23 | 2.40 | 91.1 | Supplier-supplied | 1 | MARGINAL |
| AX-2026-041455 | Retatrutide | QYB | QYB-2604-B5660 | 2026-Q3 | 99.06 | 2.70 | — | Supplier-supplied | 1 | MARGINAL |
| AX-2026-043398 | Leuprolide | WXT | WXT-2604-K4076 | 2026-Q3 | 99.22 | 5.57 | — | Supplier-supplied | 0 | PASS |